Document:

Corporate Governance and Voting Agreement

 Exhibit 4.5 
 CORPORATE GOVERNANCE 
 AND 
 VOTING AGREEMENT 
 THIS CORPORATE GOVERNANCE AND VOTING AGREEMENT (this
“Agreement”) is entered as of April 18, 2006 by and among Dr. Patrick Soon-Shiong (“PSS”), and the other persons executing signature pages hereto (PSS and such other persons, together with any third party
related to any PSS Party who hereafter becomes a signatory hereto as contemplated by Section 2.05, the “PSS Parties”), and American Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”).

 WHEREAS, the Company, American BioScience, Inc., a California Corporation (“ABI”), PSS, and certain other ABI
shareholders have entered into an Agreement and Plan of Merger, dated as of November 27, 2005 (the “Merger Agreement”) pursuant to which, among other things, ABI shall be merged with and into the Company (the
“Merger”), and all outstanding shares of capital stock of ABI shall be converted into the right to receive shares of Company Common Stock, all upon the terms and subject to the conditions set forth in the Merger Agreement;

 WHEREAS, concurrently with the execution of this Agreement, the PSS Parties are entering into a Registration Rights Agreement dated as of
the date hereof (the “RRA”) which, among other things, sets forth certain registration rights granted by the Company to the PSS Parties and certain other recipients of Company Common Stock pursuant to the Merger; 
 WHEREAS, immediately prior to the Merger, the PSS Parties own approximately 99% of the outstanding shares of ABI capital stock and desire that the Merger
be completed pursuant to the Merger Agreement; 
 WHEREAS, as an inducement for the Company to enter into the Merger Agreement, ABI has
agreed that it is a condition to the Company’s obligation to consummate the Merger that the PSS Parties execute and deliver this Agreement and thereby establish (a) certain terms and conditions concerning the voting of and future
acquisitions of Company Common Stock by the PSS Parties and their respective Affiliates, and (b) certain other matters concerning the corporate governance of the Company; and 
 WHEREAS, certain terms used herein are defined in Article IV hereof. 
 NOW, THEREFORE, in consideration of the foregoing and the mutual promises and agreements contained herein, the parties hereto hereby agree as follows:

 ARTICLE I 
 STOCK OWNERSHIP 
 SECTION 1.01. Acquisitions of Company Common Stock. Each PSS Party shall not, and shall not
permit any of his or its Affiliates to, acquire Beneficial Ownership of any 

 
shares of Company Common Stock, in each case whether by tender offer, market purchase, privately-negotiated purchase, merger or other transaction, through
the use of a derivative instrument or voting agreement, by joining a Group, or otherwise, except for: 
 (a) acquisitions of
Beneficial Ownership of Company Common Stock pursuant to the Merger; 
 (b) acquisitions of Beneficial Ownership of Company
Common Stock approved in advance by a majority of the Outside Independent Directors then in office; 
 (c) acquisitions of
Beneficial Ownership of Company Common Stock (i) upon the exercise of options to acquire Company Common Stock held by PSS or any of his Affiliates as of the date hereof or (ii) as a result of the grant of options to acquire Company Common
Stock hereafter approved by the Company Board and the Outside Independent Directors or the exercise of any such options; 
 (d) acquisitions of Company Common Stock that would not cause the PSS Parties and their respective Affiliates collectively to Beneficially Own more than 83.5% of the then-outstanding shares of Company Common Stock; and 
 (e) acquisitions of Company Common Stock pursuant to, or after the consummation of, a Qualifying Tender Offer. 
 ARTICLE II 
 CORPORATE
GOVERNANCE 
 SECTION 2.01. Outside Independent Directors. 
 (a) At each meeting of the stockholders of the Company, or in connection with any action by written consent, occurring prior to (but not
including) the 2007 Annual Meeting at which at least three Outside Independent Director candidates have been nominated for election by the Company, each PSS Party shall vote or cause to be voted all of such PSS Party’s Voting Control Shares in
favor of the election of three Outside Independent Director candidates. 
 (b) Prior to (but not including) the 2007 Annual
Meeting, no PSS Party shall permit any of such PSS Party’s Voting Control Shares to be voted (or permit any written consent to be executed in respect of any of such PSS Party’s Voting Control Shares) in favor of the removal of any Outside
Independent Directors, unless after giving effect to the removal of such Outside Independent Directors and any simultaneous or nearly simultaneous election or appointment of any directors, the Board will include at least three Outside Independent
Directors. 
 SECTION 2.02. Proxy Solicitation. No PSS Party shall, and each shall not permit its Affiliates to, directly or
indirectly solicit, or be a participant in the solicitation of, proxies from stockholders of the Company for the purpose of opposing a solicitation conducted by or on behalf of the Company or the Company Board; provided, that the foregoing
shall not (a) prevent 

  

 2 

 
any PSS Party or any of its Affiliates, in his, her or its capacity as a stockholder of the Company, from nominating candidates for election as directors of
the Company or presenting proposals for a vote or consent of the stockholders of the Company or (b) restrict the ability of any PSS Party or any of its Affiliates from voting or executing consents in respect of shares of Company Common Stock
Beneficially Owned by a PSS Party or any of its Affiliates (or causing such shares to be voted or consents executed in respect thereof) in their discretion on all matters submitted for a vote or consent of the stockholders of the Company.

 SECTION 2.03 Board Action. The Company, subject to the Company Board’s fiduciary duties, shall take all necessary and
desirable actions within its control (including calling special meetings of the Company Board and the stockholders of the Company) to effectuate the provisions and intent of this Agreement. 
 SECTION 2.04. Restrictions on Business Combinations. No PSS Party shall, or permit any of its Affiliates to, (a) merge or consolidate
with or into the Company or any of its majority-owned subsidiaries, or (b) acquire from the Company and/or any of its majority owned subsidiaries, by purchase, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction
or in a series of related transactions), except proportionately as a stockholder of the Company, assets of the Company or any of its majority-owned subsidiaries having an aggregate market value equal to 10% or more of either the aggregate market
value of all of the assets of the Company determined on a consolidated basis or the aggregate market value of all of the outstanding shares of Company Common Stock, unless such transaction is approved in advance by a majority of the Outside
Independent Directors (and the other directors of the Company Board, to the extent required by applicable law); provided, that the foregoing shall not apply to prevent any PSS Party or any of its Affiliates from merging (or require the
approval of a majority of the Outside Independent Directors in order for any PSS Party or any of its Affiliates to merge) with the Company after the consummation of a Qualifying Tender Offer. 
 SECTION 2.05 No Circumvention. No PSS Party shall, or permit its Affiliates to, take any action, or refrain from taking any action, that would
cause any Voting Control Shares to cease to constitute Voting Control Shares prior to the termination of this Agreement; provided, however, that sales or transfers of Voting Control Shares to unrelated third parties on
arm’s-length terms, or transfers to related third parties who as a condition to such transfer execute and deliver a counterpart signature page hereto and thereby become a PSS Party, shall not be deemed to be a violation of this
Section 2.05. 
 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES 
 SECTION 3.01 Representations and Warranties of PSS and the PSS Parties. PSS and
each other PSS Party hereby jointly and severally represents and warrants to the Company, as follows: 
 (a) Each PSS Party
(if it is an entity) is duly incorporated or otherwise organized, validly existing and in good standing under the laws of its jurisdiction of incorporation or organization is duly qualified or licensed to do business, and is in good 

  

 3 

 
standing, in each jurisdiction where the character of the properties owned, leased or operated by it or the nature of its business makes such qualification,
licensing or good standing necessary, except for such failures to be so duly incorporated or organized, validly existing or in good standing, qualified or licensed that, individually or in the aggregate, would not reasonably be expected to have a
material adverse effect on such PSS Party’s ability to perform its obligations hereunder. 
 (b) Each PSS Party (if it is
an entity) has all necessary corporate or other power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement by
each PSS Party (if it is an entity), the performance by such PSS Party (if it is an entity) of its obligations hereunder and the consummation by such PSS Party (if it is an entity) of the transactions contemplated hereby (i) have been duly and
validly authorized by all necessary corporate or other organizational action required on the part of such PSS Party (if it is an entity) under applicable law or the organizational, constituent or governing documents of such PSS Party (if it is an
entity), and (ii) (assuming compliance with all requirements of applicable securities laws and the rules and regulations of the NASDAQ National Market or any exchange upon which the Company’ securities are listed or traded and that the
consents, approvals, authorizations and permits described in Section 4.5(b) of the Company’s disclosure schedule to the Merger Agreement have been obtained and all filings and notifications described in such section of the Company’s
disclosure schedule have been made and any waiting periods thereunder have terminated or expired) no other consents, approvals, actions, proceedings or authorizations are necessary to authorize the execution and delivery of this Agreement by the PSS
Parties or the performance of their respective obligations hereunder, except as would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on such PSS Party’s ability to perform its obligations
hereunder. This Agreement has been duly and validly executed and delivered by each PSS Party and constitutes a legal, valid and binding obligation of each PSS Party, enforceable against such PSS Party in accordance with its terms, subject to
bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors’ rights and to general principles of equity. The trustee(s) listed on the signature page hereof
with respect to the respective PSS Parties who are trusts have the full right, power and authority to cause such trusts to comply with the terms hereof without any instructions, directions, authorizations, or approvals of any beneficiary thereof or
any other person, or have obtained all necessary instructions, directions, authorizations, or approvals. 
 (c) The execution
and delivery of this Agreement by each PSS Party does not, and the performance of this Agreement by the PSS Parties will not, (i) conflict with or violate any provision of the organizational, constituent or governing documents of such PSS Party
(if that PSS Party is an entity), (ii) conflict with or violate any organizational documents of any Affiliate of such PSS Party, or (iii) (assuming compliance with all requirements of applicable securities laws and the rules and
regulations of the NASDAQ National Market or any exchange upon which the Company’ securities are listed or traded and that the consents, approvals, authorizations and permits described in Section 4.5(b) of the Company’s disclosure
schedule to the Merger Agreement have been obtained and all filings and notifications described in such section of the Company’s disclosure schedule have been made and any waiting periods thereunder have terminated or expired) conflict with or
violate any contract binding on or any 

  

 4 

 
statute, law or order applicable to such PSS Party or by which any property or asset of such PSS Party is bound, except as would not, individually or in the
aggregate, reasonably be expected to materially limit or delay such PSS Party’s ability to perform its obligations hereunder. There are no contractual, legal or other restrictions or impediments to the right, authority and ability of the PSS
Parties to agree to and perform, and to cause such respective PSS Parties’ Affiliates to perform, the obligations contemplated hereby, except as would not, individually or in the aggregate, reasonably be expected to materially limit or delay
such PSS Party’s ability to perform its obligations hereunder. 
 (d) All shares of Company Common Stock issued to the
PSS Parties pursuant to the Merger are Voting Control Shares for purposes of this Agreement. 
 SECTION 3.02 Representations and
Warranties of the Company. The Company hereby represents and warrants to the PSS Parties, as follows: 
 (a) The Company
is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Company is duly qualified or licensed to do business, and is in good standing, in each jurisdiction where the character of the
properties owned, leased or operated by it or the nature of its business makes such qualification, licensing or good standing necessary, except for such failures to be so qualified, licensed or in good standing that individually or in the aggregate,
would not reasonably be expected to have a Company Material Adverse Effect (as defined in the Merger Agreement). 
 (b) The
Company has all necessary corporate power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement, the performance
by the Company of its obligations hereunder and the consummation by the Company of the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action on the part of the Company, and no other corporate
proceedings on the part of the Company are necessary to authorize this Agreement or to consummate the transactions contemplated hereby. This Agreement has been duly authorized and validly executed and delivered by the Company and constitutes a
legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating
to or affecting creditors’ rights and to general principles of equity. 
  

 5 

 (c) The execution and delivery of this Agreement by the Company does not, and the
performance of this Agreement by the Company will not, (i) conflict with or violate any provision of the organizational or governing documents of the Company, (ii) conflict with or violate any organizational documents of any of the
subsidiaries of the Company, or (iii) (assuming that all consents, approvals, authorizations and permits described in Section 4.5(b) of the Company’s disclosure schedule to the Merger Agreement have been obtained and all filings and
notifications described in such section of the Company’s disclosure schedule have been made and any waiting periods thereunder have terminated or expired) conflict with or violate any statute, law or order applicable to the Company or any of
its subsidiaries or by which any property or asset of the Company or any of its subsidiaries is bound or affected. 
 ARTICLE IV

 DEFINITIONS 
 SECTION 4.01 Definitions. The following terms as used herein have the following respective meanings: 
 “2007
Annual Meeting” means the annual meeting of the stockholders of the Company held in calendar year 2007. 
 “Affiliate” with respect to any person means (i) if such person is an individual, any spouse or minor child (natural or by adoption) of such person; (ii) any trust or family partnership established by such person
(if such person is an individual) and/or his or her spouse for the benefit of such person and/or members of his or her immediate family; (iii) the estate of such person (if such person is an individual); or (iv) any entity that, directly,
or indirectly through one or more intermediaries controls, is controlled by or is under common control with, such person. For purposes of this definition, “control” means the possession, directly or indirectly, of the power to direct the
management and policies of the applicable entity, whether through the ownership of voting securities, by contract or otherwise. For purposes of Section 1.01 of this Agreement and subject to the next sentence, a person shall not be considered an
“Affiliate” of a PSS Party for purposes of the provisions of this Agreement obligating a PSS Party to cause its “Affiliates” to take or refrain certain actions if that PSS Party does not possess, directly or indirectly, the power
to cause such person to comply with the requirements of such provision, whether through the ownership of voting securities, by contract or otherwise. For purposes of this Agreement, neither the Company nor any person controlled by the Company or
their respective officers and directors (other than PSS) shall be deemed to be Affiliates of any PSS Party. 
 “Beneficial
Ownership” (and related terms such as “Beneficially Owns” or “Beneficial Owner”) has the meaning set forth in Rule 13d-3 promulgated under the Exchange Act; provided, however; that for purposes of
determining Beneficial Ownership, a person or entity shall be deemed to Beneficially Own any securities which such person has the right to acquire (irrespective of whether such right to acquire such securities is exercisable immediately or only
after the passage of time, the satisfaction of any conditions, the occurrence of any event or any combination of the foregoing) pursuant to any agreement or upon the exercise of conversion 

  

 6 

 
rights, exchange rights, warrants or options, or otherwise; provided, however, that a person shall not be deemed to Beneficially Own any
securities tendered pursuant to a tender or exchange offer made by such person until such tendered securities are accepted for purchase or exchange by such person. For purposes of this Agreement, no PSS Party or any of their respective Affiliates
shall be deemed to Beneficially Own any securities Beneficially Owned by the Company or any person controlled by the Company or any of their respective officers and directors (other than PSS). Under this Agreement, for purposes of calculating the
percentage of the outstanding shares of Company Common Stock Beneficially Owned by any person or persons, the number of outstanding shares of Company Common Stock shall be deemed to include the total number of basic shares of Company Common Stock
then outstanding plus the number of shares of Company Common Stock issuable upon exercise of stock options which are then “in the money,” calculated as follows: the number of option shares to be counted in shares outstanding is calculated
individually for each tranche of options (e.g. if the company has 100 tranches, a number of shares potentially issued is calculated for each), in each case by multiplying the number of shares subject to options outstanding per tranche by the
difference between the current stock price and the strike price of the applicable tranche of option, and then dividing such number by the then current stock price. For all those tranches for which the strike price is higher than the current
stock price, the shares subject to the options are not considered to be outstanding. 
 “Company Board” means the board of
directors of the Company and, from and after the effective time of the Merger, the board of directors of the corporation surviving the Merger. 
 “Company Common Stock” means shares of common stock, par value $0.001 per share, of the Company, and any capital stock into or for which such common stock hereafter may be converted or exchanged pursuant to a
recapitalization, reclassification, merger or other similar event. 
 “Exchange Act” means the Securities Exchange Act of
1934, as amended, and any Rules promulgated thereunder. 
 “Group” has the same meaning as described in
Section 13(d)(3) of the Exchange Act. 
 “Outside Independent Directors” means any director of the Company (a) who
either (i) qualifies as an “independent director” with respect to the Company pursuant to Section 4200(a)(15) of the Nasdaq National Market Marketplace Rules (as in effect as of the date of the Merger Agreement), or
(ii) qualifies as “independent” with respect to the Company under Rule 10A-3 under the Exchange Act (as in effect as of the date of the Merger Agreement), and (b) whose nomination or appointment was approved by PSS and a majority
of the Outside Independent Directors then in office (in each case such approval not to be unreasonably withheld), it being understood that, for purposes of this clause (b), each of the individuals who is a director of the Company as of the date of
the Merger Agreement and who satisfies the requirements of clause (a) shall be deemed to have been approved by PSS and a majority of the Outside Independent Directors. 
 “person” means any individual, corporation, limited liability company, partnership, association, trust, unincorporated organization or
other entity. 
  

 7 

 “Qualifying Tender Offer” means a tender or exchange offer by PSS, one or more
Affiliates of PSS and/or one or more other PSS Parties that (i) is for all of the outstanding shares of Company Common Stock (provided, that such tender or exchange offer need not seek to acquire shares of Company Common Stock
Beneficially Owned by PSS, any of his Affiliates or any of the other PSS Parties); (ii) is subject to a non-waiveable condition that a majority of the then-outstanding shares of Company Common Stock (other than any shares of Company Common
Stock Beneficially Owned by PSS or any of his Affiliates) be validly tendered and accepted for purchase by the offeror; and (iii) includes a commitment by the offeror (to be contained in the offer to purchase pursuant to which the tender or
exchange offer is made) to promptly consummate a merger following the completion of the tender or exchange offer, in which all remaining shares of Company Common Stock not Beneficially Owned by PSS, any of his Affiliates or the PSS Parties shall be
acquired for the same amount and type of consideration as was paid per share of Company Common Stock pursuant to the tender or exchange offer. 
 “Voting Control Shares” shall mean, with respect to any PSS Party, any shares of Company Common Stock Beneficially Owned by such PSS Party or any of its Affiliates over which such PSS Party has the power to vote or control
or direct the voting thereof. 
 ARTICLE V 
 MISCELLANEOUS 
 SECTION 5.01. Notices. All notices, requests and other communications to
any party hereunder shall be in writing (including faxes or similar writing) and shall be given, 
 If to the Company, to: 
 American Pharmaceutical Partners, Inc. 
 1501 East Woodfield Road, Suite 300 East 
 Schaumburg, IL 60173-5837 
 Attention: General Counsel 
 Fax: (847) 413-2670 
 with a copy (which shall not constitute notice) to: 
 Gibson, Dunn & Crutcher LLP 
 333 South Grand Avenue 
 Los Angeles, California 90071-3197 
 Attention: Peter Ziegler, Esq. 
 Fax: (213) 229-7520 
 and further copies (which shall not constitute notice) to: 
 Morrison & Foerster LLP 
 400 Capitol Mall, Suite 2600 
 Sacramento, California 95814 
 Attention: Charles Farman, Esq. 
 Fax: (415) 268-7522 
  

 8 

 and: 
 Morrison & Foerster LLP 
 425 Market Street 
 San Francisco, California 94105-2482 
 Attention: Michael G. O’Bryan, Esq. 
 Fax: (415) 268-7522 
 If to any PSS Party to the address of such party set forth beneath such party’s signature hereto, 
 or such other address or fax number as such party may hereafter specify for such purpose by notice to the other parties hereto. Each such notice, request or other
communication shall be effective (i) if given by fax, when such fax is transmitted to the fax number specified in this Section and electronic confirmation of transmission is received or (ii) if given by any other means, when delivered
at the address specified in this Section. 
 SECTION 5.02. Amendments; No Waivers; Enforcement. 
 (a) Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an
amendment, by PSS and the Company, or in the case of a waiver, by the party against whom the waiver is to be effective; provided, that no such amendment or waiver on behalf of the Company shall be effective without the approval of (i) a
majority of the Outside Independent Directors, or (ii) if no member of the Company Board meets the definition of an Outside Independent Director, a majority of the members of the audit committee of the Company. 
 (b) Any action to be taken by the Company to amend, modify, waive, suspend or enforce its rights under this Agreement shall be taken at the direction of
a majority of the Outside Independent Directors or, if no member of the Company Board meets the definition of an Outside Independent Director, a majority of the members of the audit committee of the Company. 
 (c) No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or
partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law.

 SECTION 5.03. Headings. The headings contained in this Agreement are for reference purposes only and shall not affect in any
way the meaning or interpretation of this Agreement. 
 SECTION 5.04. Severability. If any term or other provision of this
Agreement is invalid, illegal or incapable of being enforced under applicable law or for reasons of public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or
legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination 

  

 9 

 
that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that transactions contemplated hereby are fulfilled to the extent possible. 
 SECTION 5.05. Entire Agreement. This Agreement, the Merger Agreement and the RRA represent the entire agreement of the parties and supersede
all prior or contemporaneous oral or written agreements and undertakings between the parties with respect to the specific collective subject matter hereof and thereof (it being understood that the execution and delivery hereof shall not affect the
validity or enforceability of the Merger Agreement, the RRA and the other documents and instruments executed and delivered concurrently herewith in accordance with the Merger Agreement’s terms). 
 SECTION 5.06. Assignment. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the
parties hereto, in whole or in part (whether by operation of law or otherwise), without the prior written consent of the other parties (and, in the case of any such purported assignment by any PSS Party, without the prior written consent of the
Outside Independent Directors or, if no member of the Company Board meets the definition of an Outside Independent Director, a majority of the members of the audit committee of the Company), and any attempt to make any such assignment without such
consent shall be null and void ab initio. 
 SECTION 5.07. Parties in Interest. This Agreement shall be binding upon and inure
solely to the benefit of the parties hereto and their respective successors and assigns, and nothing expressed or implied in this Agreement is intended to or shall confer upon any other person any right, benefit or remedy of any nature whatsoever
under or by reason of this Agreement. 
 SECTION 5.08. Mutual Drafting. Each party hereto has participated in the drafting of
this Agreement, which each party acknowledges is the result of extensive negotiations between the parties. As a result, the parties expressly acknowledge and agree that no principles of contractual interpretation (whether statutory or under common
law) purporting to construe ambiguities against the drafter shall apply to the interpretation, application or enforcement of this Agreement. 
 SECTION 5.09. Governing Law; Consent to Jurisdiction; Waiver of Trial by Jury. 
 (a) This Agreement shall be governed
by, and construed in accordance with, the law of the State of Delaware, without regard to its conflicts or choice of law principles. 
 (b)
Each of the parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of any Delaware State court, or Federal court of the United States of America, sitting in Delaware, and any
appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby or for recognition or enforcement of any judgment relating hereto, and each of the parties hereby
irrevocably and unconditionally (i) agrees not to commence any such action or proceeding except in such courts, (ii) agrees that any claim in 

  

 10 

 
respect of any such action or proceeding may be heard and determined in such Delaware State court or, to the extent permitted by law, in such Federal court,
(iii) waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any such action or proceeding in any such Delaware State or Federal court and (iv) waives,
to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such Delaware State or Federal court. Each of the parties hereto agrees that a final judgment in any such action or
proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Each party to this Agreement irrevocably consents to service of process in the manner provided for notices in
Section 5.01. Nothing in this Agreement will affect the right of any party to this Agreement to serve process in any other manner permitted by Law. 
 (c) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES
ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.
EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (i) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE EITHER OF SUCH WAIVERS,
(ii) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (iii) IT MAKES SUCH WAIVERS VOLUNTARILY, AND (iv) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS
IN THIS SECTION 5.09(c). 
 SECTION 5.10. Counterparts. This Agreement may be executed by facsimile signature and in two
or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. 
 SECTION 5.11. Specific Performance. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions, without the posting of any bond, to prevent breaches of
this Agreement and to enforce specifically the terms and provisions hereof, this being in addition to any other remedy to which they may be entitled at law or in equity. 
 SECTION 5.12 Termination. This Agreement automatically shall terminate upon the earliest of (a) the date of the 2007 Annual Meeting, (b) the first date upon which the PSS Parties and their
respective Affiliates collectively Beneficially Own less than 65% of the then outstanding shares of Company Common Stock and (c) the date a Qualifying Tender Offer and 

  

 11 

 
the related back-end merger are completed and all outstanding shares of Company Common Stock are owned by PSS or his Affiliates. 
 [signature page follows] 
  

 12 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the day and
year first above written. 
  

	
	PSS
	
	/s/ Dr. Patrick Soon-Shiong
	 Dr. Patrick Soon-Shiong

 Address: 
 c/o American Pharmaceutical Partners, Inc. 
 11777 San Vicente Blvd., Suite 550 
 Los Angeles, CA 90049 
  

			
	CALIFORNIA CAPITAL LIMITED PARTNERSHIP
		
	By:	 	Themba LLC, its general partner
		
	By:	 	/s/ Steven H. Hassan
		 	 Name: Steven H. Hassan

		 	 Title: Manager

 Address: 
 Californian Capital Limited Partnership 
 Att: Steven H. Hassan 
 10182 Culver Boulevard 
 Culver City, California 90232 
  

			
	THEMBA 2005 TRUST I
		
	By:	 	/s/ Steven H. Hassan
		 	 Name: Steven H. Hassan

		 	 Title: Trustee

 Address: 
 Themba 2005 Trust I 
 Att: Steven H. Hassan 
 10182 Culver Boulevard 
 Culver City, California 90232 
  

 13 

			
	THEMBA 2005 TRUST II
		
	By:	 	/s/ Steven H. Hassan
		 	 Name: Steven H. Hassan

		 	 Title: Trustee

 Address: 
 Themba 2005 Trust II 
 Att: Steven H. Hassan 
 10182 Culver Boulevard 
 Culver City, California 90232 
  

			
	THE 2005 TWO-YEAR ANNUITY TRUST A
		
	By:	 	/s/ Steven H. Hassan
		 	 Name: Steven H. Hassan

		 	 Title: Trustee

 Address: 
 The 2005 Two-Year Annuity Trust A 
 Att: Steven H. Hassan 
 10182 Culver Boulevard 
 Culver City, California 90232 
  

			
	THE 2005 TWO-YEAR ANNUITY TRUST B
		
	By:	 	/s/ Steven H. Hassan
		 	 Name: Steven H. Hassan

		 	 Title: Trustee

 Address: 
 The 2005 Two-Year Annuity Trust B 
 Att: Steven H. Hassan 
 10182 Culver Boulevard 
 Culver City, California 90232 
  

			
	THEMBA CREDIT LLC
		
	By:	 	/s/ Steven H. Hassan
		 	 Name: Steven H. Hassan

		 	 Title: Manager

 Address: 
 Themba Credit, LLC 
 Att: Steven H. Hassan 
 10182 Culver Boulevard 
 Culver City, California 90232 
  

 14 

			
	RSU PLAN LLC
		
	By:	 	/s/ Steven H. Hassan
		 	 Name: Steven H. Hassan

		 	 Title: Manager

 Address: 
 RSU Plan, LLC 
 Att: Steven H. Hassan 
 10182 Culver Boulevard 
 Culver City, California 90232 
  

			
	AMERICAN PHARMACEUTICAL PARTNERS, INC.
		
	By:	 	/s/ Nicole S. Williams
		 	 Name: Nicole S. Williams

		 	 Title: Exec. V.P. & CFO

 Address: 
 American Pharmaceutical Partners, Inc. 
 1501 East Woodfield Road, Suite 300 East 
 Schaumburg, IL 60173-5837 
 Attention: General Counsel 
 Fax: 
  

 15Escrow Agreement

 Exhibit 10.24 
 ESCROW AGREEMENT 
 This Escrow Agreement (this “Escrow Agreement”), is dated as of
April 18, 2006, by and among American Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”), Dr. Patrick Soon-Shiong, solely in his capacity as “Shareholder Representative” (the
“Shareholders’ Representative”), and Fifth Third Bank, as escrow agent (“Escrow Agent”). 
 The
Company and American BioScience, Inc., a California corporation (“ABI”), and the other parties signatory thereto are parties to an Agreement and Plan of Merger, dated as of November 27, 2005 (the “Merger
Agreement”), providing for, among other things, the merger of ABI with and into the Company (the “Merger”) with the Company as the corporation surviving the Merger. In the Merger, the outstanding shares of common stock, par
value $0.001 per share, of ABI, held by the shareholders of ABI are being converted into a right to receive shares of common stock, par value $0.001 per share, of the Company (“Company Common Stock”). Capitalized terms used but not
otherwise defined in this Escrow Agreement have the respective meanings given to them in the Merger Agreement. This is the Escrow Agreement contemplated by Section 3.1(f) of the Merger Agreement. 
 Pursuant to the Merger Agreement, the Company is depositing with the Escrow Agent a number of the shares of Company Common Stock otherwise deliverable
pursuant to the Merger to the holders of the ABI Common Stock pursuant to the Merger that is equal to 10% of the New Share Number (the “Former Shareholders”) for the purpose of providing a fund (the “Escrow Fund”)
to reimburse the Indemnified Parties for the payment of any Losses for which the Indemnified Parties are entitled to indemnification pursuant to the terms of Article IX of the Merger Agreement. 
 For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound,
hereby agree as follows: 
 1. Establishment of Escrow. 
 (a) Pursuant to the Merger Agreement, at the Effective Time, the Company shall, on behalf of the Former Shareholders, deposit with the Escrow Agent stock
certificates representing a number of shares of Company Common Stock equal to 10% of the New Share Number to create the Escrow Fund. 
 (b)
Unless and until delivered to the Company in accordance with the terms hereof, that number of shares of Company Common Stock in the Escrow Fund (and the certificates representing such shares) equal to each Former Shareholder’s Pro Rata
Percentage of the shares of Company Common Stock in the Escrow Fund shall be registered in the name of such Former Shareholder. The name and address of each of the Former Shareholders and the initial number of shares of Company Common Stock included
in the Escrow Fund to be registered in the name of such Former Shareholder are set forth on Schedule A hereto. Each Former Shareholder’s “Pro Rata Percentage” of the shares of Company Common Stock in the Escrow Fund
shall be equal to (a) the 

 
number of shares of Company Common Stock of such Former Shareholder initially included in the Escrow Fund as set forth on Schedule A hereto, divided
by (b) the total number of shares of Company Common Stock of all Former Shareholders initially included in the Escrow Fund as set forth on Schedule A hereto. 
 (c) The parties hereby designate and appoint the Escrow Agent to serve in accordance with the terms, conditions and provisions of this Escrow Agreement, and Escrow Agent hereby agrees to act as escrow agent and to
hold in trust, safeguard, invest and disburse the Escrow Fund, pursuant to the terms and conditions hereof. 
 (d) Cash, if any, or other
securities (other than shares of Company Common Stock) paid, issued or distributed in respect of shares of Company Common Stock of a Former Shareholder in the Escrow Fund (as a result of a merger, consolidation, reclassification, recapitalization,
dividend, distribution or otherwise) shall not be added to the Escrow Fund but shall be distributed to the Former Shareholder in whose name such Company Common Stock is registered 
 (e) Voting and granting consents with respect to any shares of Company Common Stock in the Escrow Fund shall be as determined by the Former Shareholder
in whose name such shares are registered in such Former Shareholder’s absolute discretion, (provided that the foregoing shall not affect the obligation of the parties to the Governance Agreement to comply with their contractual obligations
thereunder as to the voting of such shares). 
 (f) To the extent that any portion of the Escrow Fund constitutes cash, the Escrow Agent
shall invest and reinvest such cash portion of the Escrow Fund at the joint written instructions of the Company and the Shareholders’ Representative. In the absence of joint written directions from the Company and the Shareholders’
Representative, any cash in the Escrow Fund shall be invested in a money market account of a U.S. bank. 
 (g) The Escrow Agent shall, upon
receipt of a written instruction from a Former Shareholder (with a copy to the Company) and subject to documentation of the validity of such transfer reasonably acceptable to the Company, present to the transfer agent of the Company, to be
reregistered in the name of another person the name and address of which is identified in such written instruction (the “Replacement Former Shareholder”), all or a portion of such Former Shareholder’s shares of Company Common
Stock included in the Escrow Fund as shall be set forth in such written instruction. From and after such reregistration, the Replacement Former Shareholder shall be treated as the Former Shareholder pursuant to the terms of this Agreement with
respect to the shares of Common Stock reregistered in the name of the Replacement Former Shareholder. 
 2.
Indemnification Claims. 
 (a) An Indemnification Claim for Losses to be paid from the Escrow Fund pursuant to Article IX of the Merger
Agreement may be made only if the Company delivers to the Shareholders’ Representative (with a copy to the Escrow Agent) by the 

  

 2 

 
deadline for submitting such an Indemnification Claim under the Merger Agreement (the “Indemnity Termination Date”) a Claim Notice that sets
forth in reasonable detail the specific facts and circumstances giving rise to such claim and a good faith estimate of the dollar amount of the Losses for which the Indemnified Party claims it is entitled to indemnification pursuant to the terms of
the Merger Agreement (the “Indemnification Amount”). If, within thirty (30) days following receipt by the Shareholders’ Representative of a Claim Notice, the Shareholders’ Representative gives notice (a
“Counter Notice”) to the Company (with a copy to the Escrow Agent) disputing the applicable Indemnified Party’s entitlement to indemnification with respect to the Indemnification Claim set forth in a Claim Notice or disputing
the estimate set forth in such Claim Notice of the dollar amount of the Losses for which the Indemnified Party is entitled to indemnification pursuant to the terms of the Merger Agreement, the applicable Indemnified Party’s entitlement to
indemnification with respect to the Indemnification Claim and the dollar amount of the Losses for which the Indemnified Party is entitled to indemnification pursuant to the terms of the Merger Agreement shall be resolved as provided in
Section 2(c) below. 
 (b) If no Counter Notice is received by the Escrow Agent within such thirty (30) day period, then the
Indemnification Amount claimed in the applicable Claim Notice shall be deemed established for purposes of this Escrow Agreement, and, at the end of such thirty (30) day period, the Escrow Agent shall promptly deliver to the Company from the
Escrow Fund shares of Company Common Stock with a Market Value (as defined below) as of the date of the Claim Notice equal to the Indemnification Amount as claimed in the Claim Notice. The shares of Company Common Stock so delivered to the Company
from the Escrow Fund shall be disbursed from the shares of Company Common Stock of the Former Shareholders included in the Escrow Fund proportionally in accordance with their respective Pro Rata Percentages. The “Market Value” of a
share of Company Common Stock as of any day shall be equal to average of the Company Stock Prices over the ten consecutive NASDAQ trading days (or, if the Company Common Stock is not traded on the NASDAQ National Market, such number of trading days
on any other exchange or market on which the Company Common Stock is then trading) ending on and including the second full trading day preceding such day. 
 (c) (i) If a Counter Notice is given by the Shareholders’ Representative with respect to an Indemnification Claim, the Escrow Agent shall promptly (but in any event within two business days) disburse the
appropriate number of shares of Company Common Stock from the Escrow Fund in respect of such Indemnification Claim only in accordance with (A) joint written instructions of the Company and the Shareholders’ Representative, or (B) a
final judgment with no further right to appeal, upon an award rendered by a court of competent jurisdiction. 
 (ii) If the
Indemnified Party and the Shareholders’ Representative are unable to resolve any dispute within thirty (30) days of the Shareholders’ Representative’s delivery of a Counter Notice, such dispute shall be resolved in accordance
with Section 10.9 of the Merger Agreement or by means of a settlement reached between Shareholders’ Representative and the Company with respect to the applicable Indemnification Claim. 
  

 3 

 (d) If the Shareholders’ Representative and the Indemnified Party reach a settlement with respect to
any Indemnification Claim made by the Company or if the number of shares of Company Common Stock to be disbursed in respect of an Indemnification Claim is determined through a judgment not subject to appeal as provided in Section 2(c), the
Shareholders’ Representative and the Company shall jointly deliver written notice of such settlement or judgement to the Escrow Agent, including (if applicable) instructions to the Escrow Agent to disburse the appropriate number of shares of
Company Common Stock from the Escrow Fund to the Company, and the Escrow Agent shall act promptly in accordance with such instructions. The shares of Company Common Stock so disbursed to the Company from the Escrow Fund shall be disbursed
proportionally from the shares of Company Common Stock of the Former Shareholders in accordance with their respective Pro Rata Percentages. 
 (e) In the event that shares of Company Common Stock contained in the Escrow Fund are required hereunder to be disbursed to the Company, any Former Shareholder may deliver to the Company notice prior to the time of disbursement of such
shares electing to pay cash in an amount equal to the Market Value of his, her or its Pro Rata Percentage of the shares of Company Common Stock that would otherwise be disbursed from the Escrow Fund to the Company. Upon the delivery of such cash
amount by a Former Shareholder (which shall in no event occur later than two Business Days after the delivery of the notice electing to pay cash), the Company shall deliver a written instruction to the Escrow Agent to deliver to such Former
Shareholder his, her or its Pro Rata Percentage of such shares of Company Common Stock that would otherwise be disbursed from the Escrow Fund to the Company in the absence of such cash payment, and the Escrow Agent shall act in accordance with such
instructions. 
 (f) To the extent the Escrow Agent is otherwise required hereunder to disburse a fractional share of Company Common Stock of
a Former Shareholder, the Escrow Agent shall round such fractional share to the nearest whole share, with one half of such Escrow Share being rounded downward. 
 (g) The Escrow Agent shall requisition from the Company’s stock transfer agent stock certificates in appropriate denominations registered as appropriate to facilitate the delivery or disbursement by the Escrow
Agent of shares of Company Common Stock hereunder or the reregistration of shares of Company Common Stock in accordance with Section 1(g). The Company shall cause its stock transfer agent to cooperate with the Escrow Agent in connection
therewith. 
 3. Termination of Escrow. 
 (a) On the first business day following the 24 months after the Closing (the “Escrow Release Date”) and subject to Section 3(b) of this Escrow Agreement, unless any Indemnification Claims have
previously been asserted by delivery of a Claim Notice in accordance with Section 2(a) and continue to be pending, the Escrow Agent shall promptly disburse the shares of Company Common Stock in the Escrow Fund to the Former Shareholders in
accordance with their respective Pro Rata Percentages. 
  

 4 

 (b) If any Indemnification Claims were asserted by delivery of a Claim Notice in accordance with
Section 2(a) prior to the Indemnity Termination Date with respect to such Indemnification Claims and such Indemnification Claims continue to be unresolved as of the Escrow Release Date (such Indemnification Claims, “Pending
Claims”), the Escrow Agent shall disburse the shares of Company Common Stock in the Escrow Fund to the Former Shareholders in accordance with Section 3(a); provided, however, that the Escrow Agent shall exclude from such
disbursement to each Former Shareholder, and shall continue to hold in the Escrow Fund hereunder, for each Former Shareholder, that number of such Former Shareholder’s shares of Common Stock (the “Indemnity Holdback Shares”)
equal to the aggregate of (a) such Former Shareholder’s Pro Rata Percentage, multiplied by (b) the number of shares of Company Common Stock having an aggregate Market Value as of the Escrow Release Date equal to 120% of the aggregate
Indemnification Amounts of all then Pending Claims (such aggregate amount, the “Indemnification Holdback Amount”); provided, however, that, any Former Shareholder may, within 10 business days of the Escrow Release
Date, deliver to the Escrow Agent, cash (or with the approval of the Company not to be unreasonably withheld, a letter of credit) in an amount equal to (a) such Former Shareholder’s Pro Rata Percentage, multiplied by (b) the number of
shares of Company Common Stock having an aggregate Market Value as of the Escrow Release Date equal to 100% of the aggregate of the Indemnification Amounts of all such pending Indemnification Claims, in which case the Escrow Agent shall promptly
disburse to such Former Shareholder all of the Indemnity Holdback Shares of such Former Shareholder. Any such cash (or letter of credit) deposited by a Former Shareholder in lieu of Indemnity Holdback Shares shall be referred to as such Former
Shareholder’s “Escrow Assets.” After the Escrow Release Date, the Escrow Agent shall disburse or continue to hold in the Escrow Fund the Indemnity Holdback Shares or Escrow Assets of each Former Shareholder, as the case may be,
in accordance with the provisions of Section 3(b) of this Escrow Agreement. 
 (c) From and after the Escrow Release Date, each Pending
Claim for which an Indemnification Amount was included in the Indemnification Holdback Amount, shall be treated as follows: 
 (i) if a
Counter Notice relating to such Pending Claim was not timely delivered by the Shareholders’ Representative, then the Escrow Agent shall promptly thereafter disburse to the Company, with respect to each Former Shareholder, (A) such number
of such Former Shareholder’s Indemnity Holdback Shares having an aggregate Market Value (measured as of the date of the applicable Claim Notice) equal to, or (B) cash from such Former Shareholder’s Escrow Assets in an amount equal to
such Former Shareholder’s Pro Rata Percentage of the Indemnification Amount included in the Indemnity Holdback Amount and claimed in the Claim Notice relating to such Pending Claim ; and 
 (ii) if a Counter Notice relating to such Pending Claim was timely delivered by the Shareholders’ Representative, then the Escrow Agent shall
thereafter either (A) disburse to the Company and each Former Shareholder, (x) such number of such Former Shareholder’s Indemnity Holdback Shares having an aggregate Market Value equal to, or (y) cash from such Former
Shareholder’s Escrow 

  

 5 

 
Assets in an amount agreed by, and set forth in joint written instructions to the Escrow Agent from, the Company and the Shareholders’ Representative
(in which case, the date that the Market Value of the Indemnity Holdback Shares shall be calculated for purposes of paying the Pending Claims shall be specified in the joint instructions), or (B) disburse Indemnity Holdback Shares and/or cash
from such Former Shareholder’s Escrow Assets in accordance with any final judgment with no further right to appeal, upon an award rendered with respect to the Pending Claim by a court of competent jurisdiction (in which case the Market Value of
any Indemnity Holdback Shares to be disbursed to the Company to pay the Pending Claims shall be calculated based on and as of the date of such final judgment). 
 (d) In the event that PSS, his affiliates and any PSS Entities at any time become the beneficial owner of all of the outstanding shares of Company Common Stock during the term of this Agreement, the Shareholders’
Representative and the Company shall promptly deliver a joint written notice to the Escrow Agent, instructing the Escrow Agent to distribute to the Former Shareholders all the shares of Company Common Stock or Escrow Assets in the Escrow Fund, and
the Escrow Agent shall act in accordance with such instructions and thereupon the Escrow Agent’s duties hereunder shall cease and this agreement automatically shall terminate. 
 4. Duties of Escrow Agent. 
 (a) The Escrow Agent shall not be under any duty to give the Escrow Fund held by it hereunder any greater degree of care than it gives its own similar property. 
 (b) The Escrow Agent shall be entitled to rely upon any order, judgment, certification, demand, notice, instrument or other writing delivered to it hereunder without being required to determine the authenticity or the
correctness of any fact stated therein or the propriety or validity of the service thereof. The Escrow Agent may act in reliance upon any instrument or signature believed by it to be genuine and may assume that the person purporting to give receipt
or advice or make any statement or execute any document in connection with the provisions hereof has been duly authorized to do so. The Escrow Agent may conclusively presume, at any time prior to the 2007 annual meeting of the stockholders of the
Company, that any two Outside Independent Directors of the Company specified on Schedule C attached hereto (acting jointly) and, at any time after the the 2007 annual meeting of the stockholders of the Company, two members of the Company’s
audit committee (acting jointly) have the full power and authority to instruct the Escrow Agent on behalf of the Company unless written notice to the contrary is delivered by the Company to the Escrow Agent. The Company shall provide prompt written
notice to the Escrow Agent and shall deliver an updated Schedule C upon the election of successor Outside Independent Directors pursuant to the Governance Agreement, and after the 2007 annual meeting of the stockholders of the Company, the Company
shall provide a schedule reflecting the members of the audit committee from time to time in office. 
  

 6 

 (c) The Escrow Agent shall provide the Shareholders’ Representative and the Company with quarterly
reports of the status of the Escrow Fund, and shall permit the Shareholders’ Representative and representatives of the Company to inspect and obtain copies of the records of the Escrow Agent regarding the Escrow Fund, during normal business
hours and upon one business day’s prior written notice. 
 (d) The Escrow Agent may act pursuant to the advice of counsel with respect
to any matter relating to this Escrow Agreement and shall not be liable for any action taken or omitted by it in good faith in accordance with such advice. 
 (e) The Escrow Agent does not have any interest in the Escrow Fund deposited hereunder but is serving as escrow holder only to administer the Escrow Fund in accordance with the terms hereof. 
 (f) The Escrow Agent makes no representation as to the validity, value, genuineness or the collectability of any security or other document or instrument
held by or delivered to it. 
 (g) The Escrow Agent shall not be called upon to advise any party as to the wisdom in selling or retaining or
taking or refraining from any action with respect to any securities or other property deposited hereunder. 
 (h) The Escrow Agent may resign
as the Escrow Agent by notice to the other parties hereto (the “Resignation Notice”). If, prior to the expiration of sixty (60) business days after the delivery of the Resignation Notice, the Escrow Agent shall not have
received written instructions from the Shareholders’ Representative and the Company designating a banking corporation or trust company organized either under the laws of the United States or of any state as successor escrow agent and consented
to in writing by such successor escrow agent, the Escrow Agent may apply to a court of competent jurisdiction to appoint a successor escrow agent. Alternatively, if the Escrow Agent shall have received such written instructions from the Company and
the Shareholders’ Representative, it shall promptly transfer the Escrow Fund to such successor escrow agent. Upon the appointment of a successor escrow agent and the transfer of the Escrow Fund thereto, the duties of the Escrow Agent hereunder
shall terminate. 
 (i) In the event of any disagreement between the other parties hereto resulting in adverse claims or demands being made
in connection with the Escrow Fund, or in the event that the Escrow Agent is in doubt as to what action it should take hereunder, the Escrow Agent shall be entitled to (a) retain the Escrow Fund until the Escrow Agent shall have received
(i) judgment upon an award rendered by a court of competent jurisdiction directing delivery of the Escrow Fund (or portion thereof), or (ii) a written agreement executed by the Shareholders’ Representative and the Company directing
delivery of the Escrow Fund (or portion thereof); or (b) be permitted to interplead all of the Escrow Fund held hereunder into a court of competent jurisdiction described in Section 10.9 of the Merger Agreement, and thereafter be fully
relieved from any and all liability or obligation with respect to such interpleaded assets. The parties hereto other than the Escrow Agent further agree to pursue any redress or recourse in connection with such a dispute, without making the Escrow
Agent a party to same. 
  

 7 

 (j) The Escrow Agent shall not be liable for any action taken or omitted under this Escrow Agreement so
long as it shall have acted in good faith and without gross negligence. 
 (k) The Escrow Agent shall never be required to use or advance its
own funds or otherwise incur personal financial liability in the performance of any of its duties or the exercise of any of its rights and powers hereunder. 
 (l) The Escrow Agent shall have the right to perform any of its duties hereunder through agents, attorneys, custodians or nominees selected in good faith. 
 (m) Any banking association or corporation into which the Escrow Agent may be merged, converted or with which the Escrow Agent may be consolidated, or
any corporation resulting from any merger, conversion or consolidation to which the Escrow Agent shall be a party, or any banking association or corporation to which all or substantially all of the corporate trust business of the Escrow Agent shall
be transferred, shall succeed to all the Escrow Agent’s rights, obligations and immunities hereunder without the execution or filing of any paper or any further act on the part of any of the parties hereto, anything herein to the contrary
notwithstanding. 
 (n) This Escrow Agreement expressly sets forth all the duties of the Escrow Agent, which shall be deemed purely
ministerial in nature with respect to any and all matters pertinent hereto. The Escrow Agent shall under no circumstance be deemed a fiduciary for any of the parties to this Escrow Agreement. No implied duties or obligations shall be read into this
Escrow Agreement against the Escrow Agent. The Escrow Agent shall not be bound by the provisions of any agreement among the other parties hereto except this Escrow Agreement. IN NO EVENT SHALL THE ESCROW AGENT BE LIABLE, DIRECTLY OR INDIRECTLY, FOR
ANY (i) DAMAGES OR EXPENSES ARISING OUT OF THE SERVICES PROVIDED HEREUNDER, OTHER THAN DAMAGES WHICH RESULT FROM THE ESCROW AGENT’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, OR (ii) SPECIAL OR CONSEQUENTIAL DAMAGES, EVEN IF THE ESCROW
AGENT HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
  

 8 

 5. Notices. 
 Any notices or other communications required or permitted under, or otherwise made or given in connection with this Escrow Agreement, shall be in writing and shall be deemed to have been duly given when delivered in
person or upon confirmation of receipt when transmitted by facsimile transmission (but only if followed by transmittal by national overnight courier or hand for delivery on the next business day) or on receipt after dispatch by registered or
certified mail, postage prepaid, addressed, or on the next business day if transmitted by national overnight courier, in each case as follows: 
 If to the
Company, addressed to it at: 
 American Pharmaceutical Partners, Inc. 
 1501 East Woodfield Road, Suite 300 East 
 Schaumburg, IL 60173-5837 
 Attention: General Counsel 
 Fax: (847) 413-2670 
 with a copy (which shall not constitute notice) to: 
 Gibson, Dunn & Crutcher LLP 
 333
South Grand Avenue 
 Los Angeles, California 90071-3197 
 Attention: Peter F. Ziegler, Esq. 
 Fax: (213) 229-7520 
 and further copies (which shall not constitute notice) to: 
 Morrison & Foerster LLP 
 425 Market Street 
 San Francisco, California 94105-2482 
 Attention: Charles Farman, Esq. and Michael G. O’Bryan, Esq 
 Fax: (415) 268-7522 
 If to the Shareholders’ Representative, addressed to him at: 
 Dr. Patrick Soon-Shiong 
 c/o American
Pharmaceutical Partners, Inc. 
 11777 San Vicente Blvd., Suite 550 
 Los Angeles, CA 90049 
 Fax:
(310) 826-7229 
  

 9 

 If to the Escrow Agent, addressed to it at: 
 Fifth Third Bank 
 1701 Golf Road, Suite 600

 Rolling Meadows, IL 60008 
 Attention: Frank Portner 
 Facsimile: (857) 354-7060 
 6. Counterparts. 
 This Escrow
Agreement may be executed by facsimile signature and in two or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall
constitute one and the same agreement. 
 7. Fees. 
 The Company shall pay the Escrow Agent the fees set forth on Schedule B attached hereto for its services as the Escrow Agent hereunder and shall reimburse the Escrow Agent for all reasonable expenses,
disbursements and advances incurred or made by it in the performance of its duties hereunder (including, without limitation, the reasonable out-of-pocket fees, expenses and disbursements of its counsel). The Company shall indemnify and hold the
Escrow Agent harmless from and against any and all taxes, out-of-pocket expenses (including reasonable counsel fees, assessments, liabilities, claims, damages, actions, suits or other charges incurred by or assessed against it for any thing done or
omitted by it in the performance of its duties hereunder, except as a result of its own gross negligence or willful misconduct. The agreements contained in this Section 8 shall survive any termination of the duties of the Escrow Agent hereunder
or its resignation. 
 8. Section Headings. 
 The headings of sections in this Escrow Agreement are provided for convenience only and will not affect its construction or interpretation. 
 9. Amendments; No Waiver; Enforcement. 
 (a) Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by the Shareholders’ Representative, the Company and
the Escrow Agent, or in the case of a waiver, by the party against whom the waiver is to be effective; provided that no such amendment or waiver on behalf of the Company shall be effective without the approval of (i) at any time prior to the
2007 annual meeting of the stockholders of the Company, a majority of the Outside Independent Directors designated on Schedule C, as from time to time amended, or (ii) at any time after the 2007 annual meeting of the stockholders of the
Company, by a majority of the members of the audit committee of the Company. 
  

 10 

 (b) Any action to be taken by the Company to amend, modify, waive, suspend or enforce its rights under
this Agreement shall be taken at the direction of, at any time prior to the 2007 annual meeting of the stockholders of the Company, a majority of the Outside Independent Directors designated on Schedule C, as from time to time amended, or, at any
time after the 2007 annual meeting of the stockholders of the Company, by a majority of the members of the audit committee of the Company. 
 (c) No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of
any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law. 
 10. Exclusive Agreement; No Third Party Beneficiaries. 
 This Escrow Agreement and the Merger Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements and undertakings, both written and oral,
between the parties, or any of them, with respect to the subject matter hereof. This Escrow Agreement shall be binding upon and inure solely to the benefit of each party hereto and their respective successors and assigns, and nothing in this
Agreement, express or implied is intended to or shall confer upon any other person any right, benefit or remedy of any nature whatsoever under or by reason of this Escrow Agreement. 
 11. Governing Law. 
 This Escrow
Agreement shall be governed by, and construed in accordance with, the Laws of the State of Delaware, without regard to laws that may be applicable under conflicts of laws principles. It is the intention of the parties hereto that the situs of the
Escrow Fund is and shall be administered in the state in which the principal office of the Escrow Agent from time to time acting hereunder is located. 
 [signature page follows] 
  

 11 

 IN WITNESS WHEREOF, the parties have caused this Escrow Agreement to be duly executed as of the day and
year first above written. 
  

			
	AMERICAN PHARMACEUTICALS PARTNERS, INC.
		
	 By:
	 	 /s/ John F. Weidenbruch

	 Name:
	 	 John F. Weidenbruch

	 Title:
	 	 Assistance Secretary/General Counsel

  

			
	
	/s/ Patrick Soon-Shiong
	 Dr. Patrick Soon-Shiong,

	 as Shareholders’ Representative

  

			
	 Fifth Third Bank, as Escrow Agent

		
	 By:
	 	 /s/ Frank Portner

	 Name:
	 	 Frank Portner

	 Title:
	 	 Vice President

  

 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]